| Literature DB >> 25967998 |
Andrew D Beswick1, Vikki Wylde1, Rachael Gooberman-Hill1.
Abstract
OBJECTIVES: Total knee replacement can be a successful operation for pain relief. However, 10-34% of patients experience chronic postsurgical pain. Our aim was to synthesise evidence on the effectiveness of applying predictive models to guide preventive treatment, and for interventions in the management of chronic pain after total knee replacement.Entities:
Keywords: PAIN MANAGEMENT
Mesh:
Substances:
Year: 2015 PMID: 25967998 PMCID: PMC4431062 DOI: 10.1136/bmjopen-2014-007387
Source DB: PubMed Journal: BMJ Open ISSN: 2044-6055 Impact factor: 2.692
Characteristics of included study
| Author | Singh |
| Country | USA |
| Indication | Total knee replacement >6 months. Chronic pain >3 months (≥6 points on 10-point VAS scale). Unsuccessful treatment with oral pain medication, not surgical candidate or infection identified. Mean pain duration 4.5 years |
| Number of patients | 49 patients with 60 total knee replacements (30 intervention: 30 control) |
| Age | Mean: intervention 67.1 years; control 66.8 years |
| Sex | Female: intervention 22%; control 12% |
| Approach | Standardised medial or lateral |
| Intervention | Intra-articular injection of 100 units botulinum toxin A diluted in 5 mL sterile normal saline |
| Control | Intra-articular injection of 5 mL sterile normal saline |
| Follow-up interval | Up to 6 months |
| Outcome measures | Proportion of responders at 2 months (≥2 point VAS reduction) |
| Economic evaluation | None reported |
| Risk of bias | Overall: low |
| Random sequence | Independent |
| Concealment | Syringes prepared independently |
| Blinding | Patients, surgeon, investigators, statistician all blind to group allocation |
| Blind outcome | Assessment bind to group allocation |
| Complete data | Low losses to follow-up at primary outcome intervals |
| Selective reporting | Appropriate range of outcomes reported |
| Other bias | None apparent |
| Losses to follow-up | 2 (1:1) lost to 2 month follow-up. 7 (3:4) lost to 6 month follow-up |
| Power calculation | Reported to be powered for significant improvement on WOMAC scale |
| Results summary | Pain severity reduced in 71% of intervention patients compared with 35% in placebo group at 2 months. Benefit also at 3 months but not at 4 months. Duration of meaningful pain relief was 39.6 (SD=50.4) days in intervention group compared with 15.7 (SD=22.6) days in placebo group |
VAS, visual analogue scale; WOMAC, Western Ontario and McMaster Universities Osteoarthritis Index.
Figure 1Systematic review flow diagram.